Barinthus BiotherapeuticsSTU:2AB -2.73%14 Earnings Yield (Joel Greenblatt) % is 166.67% as of Mar. 2026, which is 55% above its 10-year median of 107.22. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.98. The stock has 1 warning sign investors should review. Among 1,336 Biotechnology companies, Barinthus Biotherapeutics ranks worse than 74850.22% on this metric.
Barinthus Biotherapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was €-28.18 Mil.
Barinthus Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €-45.10 Mil. Barinthus Biotherapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 166.67%.
The historical rank and industry rank for Barinthus Biotherapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
STU:2AB'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10300.83 Med: 107.22 Max: 3561.68
Current: 175.44
During the past 7 years, the highest Earnings Yield (Joel Greenblatt) of Barinthus Biotherapeutics was 3561.68%. The lowest was -10300.83%. And the median was 107.22%.
STU:2AB's Earnings Yield (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -9.745
vs STU:2AB: 175.44
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Barinthus Biotherapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Barinthus Biotherapeutics Earnings Yield (Joel Greenblatt) % Related Terms
Barinthus Biotherapeutics Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Barinthus Biotherapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Barinthus Biotherapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Barinthus Biotherapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Barinthus Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-45.10 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 166.67% mean?
Barinthus Biotherapeutics (STU:2AB) has a Earnings Yield (Joel Greenblatt) % of 166.67% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Barinthus Biotherapeutics and its competitors. This is 55% above median its historical median of 107.22. According to the industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 1336 companies in the Biotechnology industry.
Is Barinthus Biotherapeutics' Earnings Yield (Joel Greenblatt) % too high?
Barinthus Biotherapeutics' current Earnings Yield (Joel Greenblatt) % of 166.67% is 55% above median its 10-year median of 107.22. Based on the distribution chart, Barinthus Biotherapeutics ranks #999999 out of 1336 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Earnings Yield (Joel Greenblatt) % compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 1336 companies for Earnings Yield (Joel Greenblatt) %. This places Barinthus Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current Earnings Yield (Joel Greenblatt) % is 166.67%, which is 55% above median its own 10-year median of 107.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Earnings Yield (Joel Greenblatt) % of 166.67%. The stock's GF Value™ is €0.98, compared to a current price of €0.54 — trading 45.4% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 166.67%, which is 55% above median its 10-year median of 107.22. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Earnings Yield (Joel Greenblatt) % is 166.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.54 is trading 45.4% below its estimated GF Value™ of €0.98.
Key valuation signals for STU:2AB:
Earnings Yield (Joel Greenblatt) %: 166.67% (55% above median its 10-year median of 107.22)
GF Value™: €0.98 vs. price of €0.54 (45.4% below fair value)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 
